Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of BI 1744 CL in COPD
2006-004828-36Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing BI 1744 CL once-daily (various doses) with Placebo once-daily (2 arms). Primary endpoint: Trough FEV1 response after 4 weeks of treatment. Started Jan 2007; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-004828-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004828-36.